Health Condition 1: E859- Amyloidosis, unspecified Health Condition 2: C900- Multiple myeloma Health Condition 3: C901- Plasma cell leukemia
Conditions
Interventions
Intervention1: NA: NA
Control Intervention1: NA: NA
Sponsors
ACTREC, Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: -Diagnosis of plasma cell neoplasm multiple myeloma, AL amyloidosis, plasma cell leukemia or POEMS syndrome -Patients who underwent peripheral blood stem cell collection -Duration 1st September 2007 to 31st August 2024
Exclusion criteria
Exclusion criteria: Exclusion criteria -Plasma cell neoplasms who did not undergo peripheral stem cell collection -Those for whom stem cell mobilization was initiated but not completed and not undergone a stem cell harvest.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine proportion of patients with CD34+ dose more than or equal to 5x106/kg in first apheresis in various groupsTimepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| -To determine total median CD34+ dose (x106/kg) of all harvests, in four groups -Median CD34+ (x106/kg) in first apheresis, in four groups -Incidence of mobilization failure in four groups (Mobilization failure will be defined as total CD34+ dose of less than 2x106/kg or abandoned harvest attempt anticipating a poor collection) -Plerixafor subtraction analysis in groups 1, 3 and 4 (Analysis of patients who did not receive Plerixafor in groups 1,3 and 4, in order to study the inherent efficacy of a mobilization regimen, in the absence of plerixafor) -Fold increment in CD34 between one day prior to mobilization and first day of apheresis, in four groups -In patients who undergo autologous stem cell transplant in the above four groups -Incidence of engraftment syndrome -Median progression-free survival -Median overall survival Timepoint: 1 year | — |
Countries
India
Contacts
Public ContactDr Sumeet Mirgh
ACTREC TMC
Outcome results
None listed